Chronic Thromboembolic Pulmonary Hypertension

ABSTRACT

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare disease that results from obstruction of the major pulmonary arteries by incompletely resolved or organized pulmonary emboli that have become incorporated into the pulmonary artery wall, eventually causing an increase in pulmonary vascular resistance. From 0.1 to 4.0% of patients recovering from acute pulmonary embolism develop CTEPH. Without intervention, CTEPH is a progressive and lethal disease for which there is no effective medical therapy. Pulmonary endarterectomy (PEA) is the treatment of choice. Careful pre- and postoperative management is essential for a successful outcome after PEA. Lung transplantation is indicated only in few cases when PEA is not feasible. In 1994, we started a program (in Pavia, Italy) in which members of a multidisciplinary team work closely with the aim of increasing experience in the challenging problems these patients present in the evaluative, surgical, and postoperative phases of their care. To date, 134 PEAs have been performed. Preoperatively, New York Heart Association (NYHA) class distribution was three class II, 56 class III, and 75 class IV patients, respectively; mean pulmonary artery pressure and pulmonary vascular resistance values were 47 ± 13 mm Hg and 1149 ± 535 dyn/s/cm^-5, respectively. The overall operative mortality has been 9.7% (4.5% in 2004). Survival at 3-month, 1-year, and 3-year follow-up was 89.5 ± 2.6%, 87.8 ± 2.9%, and 83.3 ± 3.5%, respectively; this last rate was unchanged up to 10 years. After PEA, mean pulmonary artery pressure and pulmonary vascular resistance values were 25 ± 9 mm Hg and 322 ± 229 dyn/s/cm^-5, respectively, and these results were stable over time. At the 3-year follow-up, 94% of patients were in NYHA class I or II and were being treated with oral anticoagulants only.

Chronic pulmonary hypertension - thromboembolism - pulmonary endarterectomy - lung transplantation - anticoagulants

REFERENCES

• 1 Fedullo P F, Auger W R, Kerr K M, Rubin L J. Chronic thromboembolic pulmonary hypertension.  N Engl J Med. 2001;  345 1465-1472
• 2 Pengo V, Lensing A WA, Prins M H et al.. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism.  N Engl J Med. 2004;  350 2257-2264
• 3 Dalen J E, Banas Jr J S, Brooks H L, Evans G I, Paraskos J A, Dexter L. Resolution rate of acute pulmonary embolism in man: an angiographic study.  N Engl J Med. 1969;  280 1194-1199
• 4 Wartski M, Collignon M A. Incomplete recovery of lung perfusion after 3 months in patients with acute pulmonary embolism treated with antithrombotic agents.  J Nucl Med. 2000;  41 1043-1048
• 5 Ryan K L, Fedullo P F, Davis G B, Vasquez T E, Moser K M. Perfusion scan findings understate the severity of angiographic and hemodynamic compromise in chronic thromboembolic pulmonary hypertension.  Chest. 1988;  93 1180-1185
• 6 Wolf M, Boyer-Neumann C, Parent F et al.. Thrombotic risk factors in pulmonary hypertension.  Eur Respir J. 2000;  15 395-399
• 7 Moser K M, Auger W R, Fedullo P F, Jamieson S W. Chronic thromboembolic pulmonary hypertension; clinical picture and surgical treatment.  Eur Respir J. 1992;  5 334-342
• 8 Auger W R, Permikul P, Moser K M et al.. Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: a preliminary report.  Am J Med. 1995;  99 392-396
• 9 Olman M A, Marsh J J, Lang I M et al.. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension.  Circulation. 1992;  86 1241-1248
• 10 Lang I M, Marsh J J, Olman M A et al.. Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli.  Circulation. 1994;  90 706-712
• 11 Moser K M, Bloor C M. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension.  Chest. 1993;  103 685-692
• 12 Riedel M, Stanek V, Widimsky J, Prerovsky I. Longterm follow-up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data.  Chest. 1982;  81 151-158
• 13 Lewczuk J, Piszko P, Jagas J et al.. Prognostic factors in medically treated patients with chronic pulmonary embolism.  Chest. 2001;  119 818-823
• 14 Auger W R, Moser K M. Pulmonary flow murmurs: a distinctive physical sign found in chronic pulmonary thromboembolic disease.  Clin Res. 1989;  37 145A
• 15 Simonneau G, Azarian R, Brenot F, Dartevelle P G, Musset D, Duroux P. Surgical management of unresolved pulmonary emboli: a personal series of 72 patients.  Chest. 1995;  107 52S-55S
• 16 Morris T A, Auger W R, Ysreal M Z et al.. Parenchymal scarring is associated with restrictive spirometric defects in patients with chronic thromboembolic hypertension.  Chest. 1996;  110 399-403
• 17 Kapitan K S, Clausen J L, Moser K M. Gas exchange in chronic thromboembolism after pulmonary thromboendarterectomy.  Chest. 1990;  98 14-19
• 18 Menzel T, Wagner S, Kramm T et al.. Pathophysiology of impaired right and left ventricular function in chronic embolic pulmonary hypertension: changes after pulmonary thromboendarterectomy.  Chest. 2000;  118 897-903
• 19 King M A, Ysreal M, Bergin C J. Chronic thromboembolic pulmonary hypertension: CT findings.  AJR Am J Roentgenol. 1998;  170 955-960
• 20 Auger W R, Fedullo P F, Moser K M, Buchbinder M, Peterson K L. Chronic major vessel chronic thromboembolic pulmonary artery obstruction: appearance at angiography.  Radiology. 1992;  182 393-398
• 21 Shure D, Gregoratos G, Moser K M. Fiberoptic angioscopy: role in the diagnosis of chronic pulmonary artery obstruction.  Ann Intern Med. 1985;  103 844-850
• 22 Allison P R, Dunnill M S, Marshall R. Pulmonary embolism.  Thorax. 1960;  15 273-283
• 23 D'Armini A M, Cattadori B, Monterosso C et al.. Pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension: hemodynamic characteristics and changes.  Eur J Cardiothorac Surg. 2000;  18 696-701
• 24 Chitwood W R, Sabiston D C, Wechsler A S. Surgical treatment of chronic unresolved pulmonary embolism.  Clin Chest Med. 1984;  5 507-536
• 25 Jamieson S W, Kapelanski D P. Pulmonary endarterectomy.  Curr Probl Surg. 2000;  37 165-252
• 26 Daily P O, Dembitsky W P, Iverson S, Moser K M, Auger W. Risk factors for pulmonary thromboendarterectomy.  J Thorac Cardiovasc Surg. 1990;  99 670-678
• 27 Russo A, De Luca M, Vigna C et al.. Central pulmonary artery lesion in chronic obstructive pulmonary disease: a transesophageal echocardiography study.  Circulation. 1999;  100 1808-1815
• 28 Moser K M, Fedullo P F, Finkbeiner W E, Golden J. Do patients with primary pulmonary hypertension develop extensive central thrombi?.  Circulation. 1995;  91 741-745
• 29 Madani M M, Jamieson S W. An insider's guide to pulmonary thromboendarterectomy: proven techniques to achive optimal results.  Adv Pulm Hyperten. 2003;  2 13-20
• 30 Huisman M V, Büller H R, ten Cate J W et al.. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis.  Chest. 1989;  95 498-502
• 31 McLaughlin V V, Genthner D E, Panella M M, Hess D M, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series.  Ann Intern Med. 1999;  130 740-743
• 32 Bresser P, Fedullo P F, Auger W R et al.. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension.  Eur Respir J. 2004;  23 595-600
• 33 Kramm T, Eberle B, Krummenauer F et al.. Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy.  Ann Thorac Surg. 2003;  76 711-718